Advocacy intelligence hub — real-time data for patient organizations
INOmax: FDA approved
In conjunction with ventilatory support and other appropriate agents, in the treatment of term and near-term (>34 weeks) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, where it improves oxygenation and reduces the need for extracorporeal membrane oxygenation.
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs1
INOmax
Mallinckrodt Hospital Products
INOmax
(Nitric oxide)Orphan drugMallinckrodt Hospital Products
Vasodilator [EPC]
12.1 Mechanism of Action Nitric oxide relaxes vascular smooth muscle by binding to the heme moiety of cytosolic guanylate cyclase, activating guanylat...
Browse all Syndrome with pulmonary hypertension as a major feature news →
View all Syndrome with pulmonary hypertension as a major feature specialists →